"Dec. 14, 2012 -- Drinking a glass of beet juice may have an immediate impact on lowering blood pressure, according to a new study.
The study shows that within hours of drinking it, beet juice lowered systolic blood pressure (the top n"...
This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked.
- MAXZIDE (triamterene and hydrochlorothiazide) is indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone.
- MAXZIDE is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.).
MAXZIDE may be used alone or in combination with other antihypertensive drugs, such as beta-blockers. Since MAXZIDE (triamterene and hydrochlorothiazide) may enhance the actions of these drugs, dosage adjustments may be necessary.
Usage in Pregnancy
The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.
Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.
DOSAGE AND ADMINISTRATION
The usual dose of MAXZIDE-25 MG is one or two tablets daily, given as a single dose, with appropriate monitoring of serum potassium (see WARNINGS). The usual dose of MAXZIDE is one tablet daily, with appropriate monitoring of serum potassium (see WARNINGS). There is no experience with the use of more than one MAXZIDE tablet daily or more than two MAXZIDE-25 MG tablets daily. Clinical experience with the administration of two MAXZIDE-25 MG tablets daily in divided doses (rather than as a single dose) suggests an increased risk of electrolyte imbalance and renal dysfunction.
Patients receiving 50 mg of hydrochlorothiazide who become hypokalemic may be transferred to MAXZIDE (triamterene and hydrochlorothiazide) directly. Patients receiving 25 mg hydrochlorothiazide who become hypokalemic may be transferred to MAXZIDE-25 MG (37.5 mg triamterene/25 mg hydrochlorothiazide) directly.
In patients requiring hydrochlorothiazide therapy and in whom hypokalemia cannot be risked therapy may be initiated with MAXZIDE-25 MG. If an optimal blood pressure response is not obtained with MAXZIDE-25 MG, the dose should be increased to two MAXZIDE-25 MG tablets daily as a single dose, or one MAXZIDE tablet daily. If blood pressure still is not controlled, another antihypertensive agent may be added (see PRECAUTIONS: DRUG INTERACTIONS).
Clinical studies have shown that patients taking less bioavailable formulations of triamterene and hydrochlorothiazide in daily doses of 25 mg to 50 mg hydrochlorothiazide and 50 mg to 100 mg triamterene may be safely changed to one MAXZIDE-25 MG tablet daily. All patients changed from less bioavailable formulations to MAXZIDE should be monitored clinically and for serum potassium after the transfer.
MAXZIDE® tablets (triamterene and hydrochlorothiazide tablets, USP) are yellow bow-tie shaped, single scored tablets with B to the left of the score and M8 to the right of the score on one side of the tablet and MAXZIDE on the other side. Each tablet contains 75 mg of triamterene, USP and 50 mg of hydrochlorothiazide, USP. They are supplied as follows:
NDC 0378-0460-01 bottles of 100 tablets
NDC 0378-0460-05 bottles of 500 tablets
MAXZIDE®-25 MG tablets (triamterene and hydrochlorothiazide tablets, USP) are green bow-tie shaped, single scored tablets with B to the left of the score and M9 to the right of the score on one side and MAXZIDE on the other side. Each tablet contains 37.5 mg of triamterene, USP and 25 mg of hydrochlorothiazide, USP. They are supplied as follows:
NDC 0378-0464-01 bottles of 100 tablets
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Protect from light.
Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Revised January 2011This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 5/17/2011
Additional Maxide Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on handling your hypertension.